Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan T Vogl

Showing results (31-40 of 73) with videos related to

Pageof 8
Sort By:
Cancer Research|September 7, 2022
A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor ProgressionHui Deng, Cindy Lin, Laura Garcia-Gerique, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 23, 2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialSergio Giralt, Luciano J Costa, David Maloney, et al.
Autophagy|July 4, 2014
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myelomaDan T Vogl, Edward A Stadtmauer, Kay-See Tan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 2011
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myelomaDan T Vogl, Tao Wang, Waleska S Pérez, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Blood|August 24, 2023
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapyYan Tang, Wei Liu, Siddhant Kadu, et al.
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Blood|September 25, 2010
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trialEdward A Stadtmauer, Dan T Vogl, Eline Luning Prak, et al.
Pageof 8

Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Cancer Research|September 7, 2022
A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor ProgressionHui Deng, Cindy Lin, Laura Garcia-Gerique, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 23, 2019
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 TrialSergio Giralt, Luciano J Costa, David Maloney, et al.
Autophagy|July 4, 2014
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myelomaDan T Vogl, Edward A Stadtmauer, Kay-See Tan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 1, 2011
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myelomaDan T Vogl, Tao Wang, Waleska S Pérez, et al.
American Journal of Hematology|August 19, 2007
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell supportDan T Vogl, Stephen V Liu, Elise A Chong, et al.
Blood|August 24, 2023
Exploiting the CD200-CD200R immune checkpoint axis in multiple myeloma to enhance CAR T-cell therapyYan Tang, Wei Liu, Siddhant Kadu, et al.
Ejhaem|July 18, 2022
Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myelomaPaul G Richardson, Sundar Jagannath, Ajai Chari, et al.
The New England Journal of Medicine|September 10, 2015
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaAlfred L Garfall, Marcela V Maus, Wei-Ting Hwang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 4, 2008
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemiaDonald E Tsai, Selina M Luger, Charalambos Andreadis, et al.
Blood|September 25, 2010
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trialEdward A Stadtmauer, Dan T Vogl, Eline Luning Prak, et al.
Pageof 8